Bromopride

• CAS: 4093-35-0
• Catalog Number: ACM4093350
• Category: Main Products
• Molecular Weight: 344.25
• Molecular Formula: C14H22BrN3O2
• Synonyms: 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
• Melting Point: 148 - 150 °C
• Appearance: White to Off-White Solid

Case Study

Bromopride-Intercalated Sodium Montmorillonite Complex for Enhanced Drug Delivery

Bello M.L, et al. European Journal of Pharmaceutical Sciences, 2022, 175, 106222.

Bromopride (BPD) was successfully intercalated into sodium montmorillonite (Na-MMT) to improve its stability and controlled release properties. Na-MMT was pretreated ultrasonically at varying concentrations (0.5%-5.0% w/v) and sonication times (15-60 min), followed by freeze-drying and characterization via X-ray powder diffraction (XRPD) and dynamic light scattering (DLS). The intercalation process was optimized using different drug-to-clay ratios (90-180 mEq/100 g Na-MMT) under acidic conditions (pH 1.2) and magnetic stirring for up to 72 hours. Post-intercalation, the complexes were purified through centrifugation and rotary evaporation to remove unbound drug molecules. The resulting Na-MMT/BPD complexes exhibited enhanced dispersion, improved basal spacing, and controlled drug release, making them promising candidates for sustained-release formulations in gastrointestinal therapy.

Bromopride: Population Pharmacokinetics and Absorption Characteristics in Clinical Use

Lachi-Silva L, et al. European Journal of Pharmaceutical Sciences, 2020, 142, 105081.

Bromopride exhibits a complex absorption profile requiring advanced pharmacokinetic modeling for accurate characterization. A retrospective analysis utilizing MONOLIX 2018R2 determined that a mixed absorption model-incorporating sequential first- and zero-order kinetics-best described its atypical absorption behavior. Population pharmacokinetics parameters included a first-order absorption rate (ka) of 0.08 h⁻¹, a 32.60% fraction of dose absorbed via first-order kinetics, and a zero-order absorption duration (Tk0) of 0.88 h with a latency time (Tlag) of 0.47 h. The drug's volume of distribution (230 L) and clearance (46.80 L h⁻¹) were also characterized. Covariate analysis revealed that body weight influenced Tk0, dosage form affected both Tk0 and Tlag, and gender impacted Tlag, though clinical simulations indicated minimal impact on overall drug exposure. The mixed absorption model provided a flexible and physiologically relevant framework for understanding bromopride's pharmacokinetics, ensuring optimized dosage formulations for enhanced therapeutic efficacy.

Custom Q&A

What is the molecular formula of bromopride?

The molecular formula of bromopride is C14H22BrN3O2.

What is the molecular weight of bromopride?

The molecular weight of bromopride is 344.25 g/mol.

What are the synonyms for bromopride?

The synonyms for bromopride include Artomey, Valopride, and Bromoprida.

What is the IUPAC name of bromopride?

The IUPAC name of bromopride is 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide.

What is the InChIKey of bromopride?

The InChIKey of bromopride is GIYAQDDTCWHPPL-UHFFFAOYSA-N.

What is the canonical SMILES of bromopride?

The canonical SMILES of bromopride is CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Br.

What is the CAS number of bromopride?

The CAS number of bromopride is 4093-35-0.

What is the UNII number of bromopride?

The UNII number of bromopride is 75473V2YZK.

What is the usage of bromopride?

Bromopride is used as a dopamine antagonist and antiemetic with prokinetic properties similar to metoclopramide. However, it is unavailable in America or the United Kingdom.